Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company is headquartered in South Orange, New Jersey and currently employs 7 full-time employees. In medical device markets, its filters are generally classified as ultrafilters, and are used primarily by hospitals for the prevention of infection from water-borne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. In commercial markets, the Company manufactures and sell filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Marketed under both the Nephros and AETHER brands. The Company’s product lines are: Water Filtration Products and Specialty Renal Products (HDF System). The Company’s subsidiary, Specialty Renal Products, Inc. (SRP), is a development-stage medical device company focused primarily on developing hemodiafiltration (HDF) technology.
Website: nephros.com



Growth: Good revenue growth rate 50.0%, there is acceleration compared to average historical growth rates 27.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -13.3%. On average the margin is improving steadily. Gross margin is high, +60.5%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 140.7% higher than minimum and 79.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.6x by EV / Sales multiple , the company can be 79.3% undervalued

Insiders: For the last 3 months insiders bought company shares on $0.0 mln (0.067% of cap.)

Key Financials (Download financials)

Ticker: NEPH
Share price, USD:  (-0.5%)2.19
year average price 2.15  


year start price 1.43 2023-05-09

min close price 1.18 2023-05-22

max close price 3.91 2023-12-27

current price 2.19 2024-05-07
Common stocks: 10 386 018

Dividend Yield:  0.0%
Last revenue growth (y/y):  50.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  27.8%
Historical growth of EBITDA:  ---
EV / Sales: 1.4x
Margin (EBITDA LTM / Revenue): -13.3%
Fundamental value created in LTM:
Market Cap ($m): 23
Net Debt ($m): -1
EV (Enterprise Value): 22
Price to Book: 2.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-11-10Seeking Alpha

Nephros, Inc. (NEPH) Q3 2023 Earnings Call Transcript

2023-09-19Newsfile Corp

Nephros to Present at LD Micro Main Event XVI

2023-05-24Newsfile Corp

Nephros to Present at LD Micro Invitational XIII

2023-04-26GlobeNewsWire

Nephros Schedules First Quarter 2023 Financial Results Conference Call
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NEPH NEPH NEPH NEPH NEPH NEPH
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-15 2023-11-08 2023-08-09 2023-05-10 2023-03-23 2022-11-15
acceptedDate 2024-03-15 16:25:41 2023-11-08 16:00:48 2023-08-09 16:00:51 2023-05-10 16:07:35 2023-03-23 17:05:02 2022-11-15 16:27:08
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 3M 4M 4M 4M 3M 2M
costOfRevenue 1M 2M 1M 2M 1M 2M
grossProfit 2M 2M 2M 2M 2M 762 000
grossProfitRatio 0.605 0.586 0.586 0.571 0.590 0.316
researchAndDevelopmentExpenses 208 000 205 000 221 000 239 000 359 000 252 000
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 2M 2M 2M 2M 2M
otherExpenses -32 000 10000.000 -11 000 54 000 56 000 48 000
operatingExpenses 3M 2M 3M 2M 2M 2M
costAndExpenses 4M 4M 4M 4M 3M 4M
interestIncome 28 000 11 000 13 000 12 000 7000.000 4000.000
interestExpense 1000.000 0 0 1000.000 3000.000 4000.000
depreciationAndAmortization 51 000 56 000 54 000 55 000 33 000 83 000
ebitda -598 000 -126 000 -379 000 -251 000 -660 000 -1M
ebitdaratio -0.184 -0.034 -0.107 -0.068 -0.258 -0.497
operatingIncome -649 000 -203 000 -435 000 -306 000 -693 000 -1M
operatingIncomeRatio -0.199 -0.054 -0.123 -0.083 -0.271 -0.532
totalOtherIncomeExpensesNet -5000.000 10000.000 -11 000 -11 000 -26 000 31 000
incomeBeforeTax -654 000 -182 000 -433 000 -306 000 -719 000 -1M
incomeBeforeTaxRatio -0.201 -0.049 -0.122 -0.083 -0.281 -0.519
incomeTaxExpense 0 10000.000 -11 000 1000.000 225 000 2M
netIncome -654 000 -182 000 -433 000 -307 000 -944 000 -3M
netIncomeRatio -0.201 -0.049 -0.122 -0.083 -0.369 -1.328
eps -0.062 -0.017 -0.042 -0.030 -0.092 -0.310
epsdiluted -0.062 -0.017 -0.042 -0.030 -0.092 -0.310
weightedAverageShsOut 11M 10M 10M 10M 10M 10M
weightedAverageShsOutDil 11M 10M 10M 10M 10M 10M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NEPH NEPH NEPH NEPH NEPH NEPH
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-15 2023-11-08 2023-08-09 2023-05-10 2023-03-23 2022-11-15
acceptedDate 2024-03-15 16:25:41 2023-11-08 16:00:48 2023-08-09 16:00:51 2023-05-10 16:07:35 2023-03-23 17:05:02 2022-11-15 16:27:08
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 4M 5M 4M 4M 4M 4M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 4M 5M 4M 4M 4M 4M
netReceivables 1M 1M 2M 2M 1M 1M
inventory 2M 2M 2M 2M 3M 3M
otherCurrentAssets 132 000 173 000 152 000 177 000 188 000 316 000
totalCurrentAssets 8M 9M 8M 8M 8M 9M
propertyPlantEquipmentNet 2M 838 000 922 000 1M 1M 532 000
goodwill 759 000 759 000 759 000 759 000 759 000 759 000
intangibleAssets 652 000 693 000 737 000 780 000 825 000 868 000
goodwillAndIntangibleAssets 1M 1M 1M 2M 2M 2M
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 86 000 123 000 54 000 60 000 54 000 58 000
totalNonCurrentAssets 3M 2M 2M 3M 3M 2M
otherAssets 0 0 0 0 0 0
totalAssets 12M 11M 10M 11M 11M 11M
accountPayables 873 000 805 000 302 000 719 000 740 000 779 000
shortTermDebt 446 000 311 000 323 000 313 000 387 000 370 000
taxPayables 36 000 0 0 0 17 000 0
deferredRevenue 0 0 0 0 0 0
otherCurrentLiabilities 794 000 712 000 572 000 383 000 285 000 272 000
totalCurrentLiabilities 2M 2M 1M 1M 1M 1M
longTermDebt 1M 469 000 534 000 618 000 706 000 203 000
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 -946 000
totalNonCurrentLiabilities 1M 469 000 534 000 618 000 706 000 203 000
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 1M 780 000 857 000 931 000 1M 430 000
totalLiabilities 4M 2M 2M 2M 2M 2M
preferredStock 1.000 0 0 0 0 0
commonStock 10000.000 10000.000 10000.000 10000.000 10000.000 10000.000
retainedEarnings -144M -144M -144M -143M -143M -142M
accumulatedOtherComprehensiveIncomeLoss 0.000 0 0 0 0 0
othertotalStockholdersEquity 153M 152M 152M 152M 148M 148M
totalStockholdersEquity 8M 9M 9M 9M 6M 6M
totalEquity 8M 9M 9M 9M 6M 6M
totalLiabilitiesAndStockholdersEquity 12M 11M 10M 11M 11M 11M
minorityInterest 0 0 0 0 3M 0
totalLiabilitiesAndTotalEquity 12M 11M 10M 11M 11M 11M
totalInvestments 0 0 0 0 0 0
totalDebt 2M 780 000 857 000 931 000 1M 573 000
netDebt -2M -4M -3M -3M -3M -3M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NEPH NEPH NEPH NEPH NEPH NEPH
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-15 2023-11-08 2023-08-09 2023-05-10 2023-03-23 2022-11-15
acceptedDate 2024-03-15 16:25:41 2023-11-08 16:00:48 2023-08-09 16:00:51 2023-05-10 16:07:35 2023-03-23 17:05:02 2022-11-15 16:27:08
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -654 000 -182 000 -433 000 -306 000 -848 000 -3M
depreciationAndAmortization 51 000 56 000 54 000 53 000 55 000 100 000
deferredIncomeTax -865 000 93 000 0 0 0 0
stockBasedCompensation 390 000 149 000 194 000 319 000 179 000 254 000
changeInWorkingCapital 24 000 525 000 483 000 32 000 478 000 483 000
accountsReceivables -50 000 119 000 387 000 -677 000 88 000 756 000
inventory -391 000 -142 000 206 000 714 000 486 000 406 000
accountsPayables 68 000 502 000 -416 000 -21 000 -38 000 -632 000
otherWorkingCapital 397 000 46 000 306 000 16 000 -58 000 -47 000
otherNonCashItems 817 000 -79 000 -72 000 178 000 -59 000 2M
netCashProvidedByOperatingActivities -237 000 562 000 226 000 276 000 -195 000 -170 000
investmentsInPropertyPlantAndEquipment -75 000 0 0 0 137 000 0
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites -75 000 0 0 0 137 000 0
debtRepayment -3000.000 -77 000 -2000.000 -74 000 -80 000 -69 000
commonStockIssued 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 -66 000 0
otherFinancingActivites 0 77 000 0 0 35 000 0
netCashUsedProvidedByFinancingActivities -3000.000 -77 000 -2000.000 -74 000 -111 000 -69 000
effectOfForexChangesOnCash 0 0 0 0 2000.000 0
netChangeInCash -315 000 562 000 224 000 202 000 -306 000 -239 000
cashAtEndOfPeriod 4M 5M 4M 4M 4M 4M
cashAtBeginningOfPeriod 5M 4M 4M 4M 4M 4M
operatingCashFlow -237 000 562 000 226 000 276 000 -195 000 -170 000
capitalExpenditure -75 000 0 0 0 137 000 0
freeCashFlow -312 000 562 000 226 000 276 000 -58 000 -170 000
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-03-07 ET (fiscal 2023 q4)
2023 q3
2023-11-10 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-12 ET (fiscal 2023 q1)
2022 q4
2023-03-08 ET (fiscal 2022 q4)
2022 q3
2022-11-06 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-02 11:40 ET
Nephros Schedules First Quarter 2024 Financial Results Conference Call
2024-03-07 21:15 ET
Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
2024-02-29 21:30 ET
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results
2023-11-08 21:15 ET
Nephros Announces Results for Quarter Ended September 30, 2023
2023-11-01 11:30 ET
Nephros Hires Judy Krandel as Chief Financial Officer
2023-10-25 11:30 ET
Nephros Schedules Third Quarter 2023 Financial Results Conference Call
2023-09-19 20:30 ET
Nephros to Present at LD Micro Main Event XVI
2023-08-09 20:15 ET
Nephros Announces Results for Quarter Ended June 30, 2023
2023-07-26 11:30 ET
Nephros Schedules Second Quarter 2023 Financial Results Conference Call
2023-05-24 11:30 ET
Nephros to Present at LD Micro Invitational XIII
2023-05-10 20:15 ET
Nephros Announces Results for Quarter Ended March 31, 2023
2023-05-08 11:30 ET
Nephros Announces CEO Retirement and Succession Plan
2023-04-26 11:30 ET
Nephros Schedules First Quarter 2023 Financial Results Conference Call
2023-04-04 11:30 ET
Nephros Announces Preliminary Results for First Quarter 2023
2023-03-08 21:15 ET
Nephros Announces Fourth Quarter and Fiscal Year 2022 Financial Results
2023-03-01 21:30 ET
Nephros and Donastar Announce Strategic Partnership
2023-02-22 21:30 ET
Nephros Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call
2023-01-11 12:30 ET
Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022
2022-11-02 20:15 ET
Nephros Announces Results for Quarter Ended September 30, 2022
2022-10-19 11:30 ET
Nephros Third Quarter 2022 Financial Results Conference Call
2022-10-12 11:30 ET
Nephros to Present at LD Micro Main Event XV
2022-10-11 11:30 ET
Nephros Announces Agreement to Sell Pathogen Detection Systems Business and Preliminary Results for Quarter Ended September 30, 2022
2022-09-28 11:30 ET
Nephros Partners with Donastar and Tractor Beverage Company to Supply and Service Nationwide Fast-Casual Restaurant Operation
2022-09-08 20:00 ET
Nephros Appoints Joe Harris to Its Board of Directors
2022-08-10 20:15 ET
Nephros Announces Results for Quarter Ended June 30, 2022
2022-07-27 11:30 ET
Nephros Second Quarter 2022 Financial Results Conference Call
2022-07-06 11:30 ET
Nephros Announces Preliminary Results for Quarter Ended June 30, 2022 and Projects Positive Net Cash Flow in 12 Months
2022-05-17 11:30 ET
Nephros Receives FDA 510(k) Clearance for HDF Assist Module
2022-05-04 20:15 ET
Nephros Announces Results for Quarter Ended March 31, 2022
2022-04-27 11:30 ET
Nephros First Quarter 2022 Financial Results Conference Call
2022-04-26 11:30 ET
Nephros Unveils New Branding and Website
2022-03-21 11:30 ET
Nephros to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
2022-02-28 12:30 ET
Nephros to Present at Q1 Virtual Investor Summit
2022-02-23 21:15 ET
Nephros Announces Fourth Quarter and Fiscal Year 2021 Financial Results
2022-02-09 12:30 ET
Nephros Fourth Quarter 2021 Financial Results Conference Call
2022-01-13 12:30 ET
Nephros Issues 2022 Shareholder Letter
2022-01-11 12:30 ET
Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2021 and Revenue Guidance for 2022
2021-11-23 21:15 ET
Nephros to Present at the Benchmark Company 10th Annual One-on-One Discovery Conference
2021-11-08 12:30 ET
Nephros to Present at the Q4 Virtual Investor Summit
2021-11-04 20:15 ET
Nephros Announces Results for Quarter Ended September 30, 2021
2021-10-21 11:30 ET
Nephros Announces Third Quarter 2021 Financial Results Conference Call
2021-10-08 11:30 ET
Nephros Announces Preliminary Results for Third Quarter of 2021
2021-10-05 11:30 ET
Nephros to Present at the LD Micro Main Event
2021-09-15 13:39 ET
Nephros to Present at the Virtual MicroCap Leadership Summit
2021-09-01 11:30 ET
Nephros Appoints Wes Lobo to Chief Commercial Officer
2021-08-05 20:15 ET
Nephros Announces Results for Quarter Ended June 30, 2021
2021-07-12 11:30 ET
Nephros Announces Acquisition of GenArraytion, Inc.
2021-07-09 20:17 ET
Nephros CEO Presenting at Access to Giving Virtual Investor Conference
2021-07-08 11:30 ET
Nephros Announces Preliminary Results for Second Quarter of 2021
2021-05-06 20:15 ET
Nephros Announces Results for Quarter Ended March 31, 2021
2021-04-26 11:30 ET
Nephros Announces First Quarter 2021 Financial Results Conference Call
2021-04-05 11:30 ET
Nephros Announces Preliminary Results for First Quarter of 2021
2021-03-16 11:45 ET
Nephros to Present at the Q1 Virtual Investor Summit
2021-03-10 12:30 ET
Nephros to Participate in M-Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
2021-03-01 21:15 ET
Nephros Reports 2020 Fourth Quarter and Full Year Financial Results
2021-02-22 12:30 ET
Nephros Announces Fourth Quarter and Full Year 2020 Financial Results Conference Call
2021-02-18 12:30 ET
Nephros Hires Wes Lobo as Chief Marketing Officer
2021-01-12 12:30 ET
Nephros Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020
2021-01-04 12:30 ET
Nephros Provides Year-End Technology Update, Including HDF Program Status
2020-11-09 12:30 ET
Nephros to Present at Three November Investment Conferences
2020-11-05 21:27 ET
Nephros Appoints Dan D’Agostino as CFO and Reports Third Quarter Financial Results
2020-10-29 11:30 ET
Nephros Announces Third Quarter 2020 Financial Results Conference Call
2020-10-16 11:30 ET
Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock
2020-10-13 11:30 ET
Nephros Announces Release of DialyPath™, a qPCR-based, Real-time, On-site Endotoxin Assay for Dialysis Water
2020-10-08 19:30 ET
The MicroCap Rodeo Best Ideas Bowl 2020; October 13-16, 2020
2020-10-07 11:30 ET
Nephros to Present at MicroCap Rodeo Best Ideas Bowl on October 13th at 11:30 AM ET
2020-10-06 11:30 ET
Nephros Announces Preliminary Third Quarter Revenues of $2.1 Million
2020-08-25 11:30 ET
Nephros to Present at the LD 500 Virtual Conference
2020-08-14 11:30 ET
Nephros Names Andy Astor President and Chief Executive Officer
2020-08-05 20:15 ET
Nephros Reports Second Quarter Financial Results
2020-07-29 11:30 ET
Nephros Announces Second Quarter 2020 Financial Results Conference Call
2020-07-22 11:30 ET
Potable Water in Buildings Unoccupied During COVID-19 Pandemic Contains Far More Bacteria than in Occupied Buildings; Legionella does not Predominate
2020-07-13 11:30 ET
Nephros to Present at Zooming with LD
2020-07-08 11:30 ET
Nephros Announces Preliminary Financial Results for Second Quarter 2020
2020-06-18 11:30 ET
Nephros Set to Join Russell Microcap® Index
2020-06-02 11:30 ET
Nephros to Present at the Virtual Summer Summit
2020-05-11 20:15 ET
Nephros, Inc. to Hold Virtual Annual Meeting of Stockholders
2020-05-06 20:15 ET
Nephros Reports First Quarter Financial Results
2020-04-29 11:30 ET
Nephros Announces First Quarter 2020 Financial Results Conference Call
2020-04-02 11:30 ET
Nephros Announces Preliminary Financial Results for First Quarter 2020
2020-03-25 11:30 ET
Specialty Renal Products Announces Appointment of Tony Robinson as Vice President of Operations
2020-03-10 11:30 ET
Nephros to Present at the Sidoti Spring 2020 Investor Conference
2020-03-04 21:45 ET
Nephros, Inc to Present at the Spring Investor Summit on March 25th-26th in New York City
2020-03-03 12:30 ET
Nephros to Present at the 2020 LD Micro Virtual Conference
2020-02-27 21:05 ET
Nephros Reports 2019 Fourth Quarter and Full Year Financial Results
2020-02-20 12:30 ET
Nephros Announces Fourth Quarter and Full Year 2019 Financial Results Conference Call
2020-01-31 12:30 ET
Nephros Announces Pricing of $7.5 Million Underwritten Offering of Common Stock
2020-01-09 12:30 ET
Nephros Announces Launch of PluraPath™, a Real-Time, Portable, Water Pathogen Detection System
2020-01-06 12:30 ET
Nephros Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019
2019-11-06 12:30 ET
Nephros Reports Third Quarter Financial Results
2019-10-31 11:30 ET
Nephros Announces Third Quarter 2019 Financial Results Conference Call
2019-10-14 11:30 ET
Nephros, Inc. (Nasdaq: NEPH) to Ring The Nasdaq Stock Market Closing Bell
2019-10-07 11:30 ET
Nephros Announces Preliminary Financial Results for Third Quarter 2019
2019-03-12 11:45 ET
Nephros Reports 2018 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

SEC forms

Show financial reports only

SEC form 10
2024-03-15 16:25 ET
Nephros published news for 2023 q4
SEC form 10
2024-03-15 00:00 ET
Nephros published news for 2023 q4
SEC form 8
2024-03-07 16:15 ET
Nephros published news for 2023 q4
SEC form 8
2024-03-07 16:15 ET
Nephros reported for 2023 q4
SEC form 10
2023-11-08 16:00 ET
Nephros reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Nephros published news for 2023 q3
SEC form 6
2023-08-09 16:15 ET
Nephros published news for 2023 q2
SEC form 10
2023-08-09 16:00 ET
Nephros reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Nephros published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Nephros published news for 2023 q2
SEC form 10
2023-05-10 00:00 ET
Nephros reported for 2023 q1
SEC form 6
2023-04-04 16:00 ET
Nephros published news for 2023 q1
SEC form 8
2023-04-04 00:00 ET
Nephros published news for 2023 q1
SEC form 10
2023-03-23 17:05 ET
Nephros reported for 2022 q4
SEC form 10
2023-03-23 00:00 ET
Nephros reported for 2022 q4
SEC form 6
2023-03-08 16:25 ET
Nephros published news for 2022 q4
SEC form 8
2023-03-08 00:00 ET
Nephros reported for 2022 q4
SEC form 6
2023-02-03 07:00 ET
Nephros published news for 2022 q4
SEC form 6
2023-01-11 08:57 ET
Nephros published news for 2022 q4
SEC form 8
2023-01-11 00:00 ET
Nephros published news for 2022 q4
SEC form 6
2022-11-21 16:01 ET
Nephros published news for 2022 q3
SEC form 10
2022-11-15 16:27 ET
Nephros reported for 2022 q3
SEC form 6
2022-11-15 09:25 ET
Nephros published news for 2022 q3
SEC form 10
2022-11-15 00:00 ET
Nephros reported for 2022 q3
SEC form 6
2022-11-02 16:15 ET
Nephros published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Nephros reported for 2022 q3
SEC form 6
2022-10-11 07:30 ET
Nephros published news for 2022 q3
SEC form 6
2022-09-08 17:24 ET
Nephros published news for 2022 q2
SEC form 6
2022-08-23 16:30 ET
Nephros published news for 2022 q2
SEC form 10
2022-08-15 16:45 ET
Nephros reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Nephros reported for 2022 q2
SEC form 6
2022-08-10 16:15 ET
Nephros published news for 2022 q2
SEC form 8
2022-08-10 00:00 ET
Nephros reported for 2022 q2
SEC form 6
2022-07-06 08:51 ET
Nephros published news for 2022 q2
SEC form 8
2022-07-06 00:00 ET
Nephros published news for 2022 q2
SEC form 6
2022-05-20 16:00 ET
Nephros published news for 2022 q1
SEC form 6
2022-05-17 16:46 ET
Nephros published news for 2022 q1
SEC form 10
2022-05-05 10:53 ET
Nephros reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Nephros reported for 2022 q1
SEC form 6
2022-05-04 16:09 ET
Nephros published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Nephros reported for 2022 q1
SEC form 6
2022-04-13 16:37 ET
Nephros published news for 2022 q1
SEC form 10
2022-03-03 16:30 ET
Nephros published news for 2021 q4
SEC form 10
2022-03-03 00:00 ET
Nephros published news for 2021 q4
SEC form 6
2022-02-23 16:34 ET
Nephros published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Nephros published news for 2021 q4
SEC form 6
2022-01-13 07:30 ET
Nephros published news for 2021 q4
SEC form 8
2022-01-13 00:00 ET
Nephros published news for 2021 q4
SEC form 6
2021-12-03 16:38 ET
Nephros published news for 2021 q3
SEC form 10
2021-11-04 16:17 ET
Nephros published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Nephros published news for 2021 q3
SEC form 6
2021-10-08 07:45 ET
Nephros published news for 2021 q3
SEC form 8
2021-10-08 00:00 ET
Nephros published news for 2021 q3
SEC form 6
2021-09-02 08:53 ET
Nephros published news for 2021 q2
SEC form 6
2021-08-05 16:27 ET
Nephros published news for 2021 q2
SEC form 10
2021-08-05 16:16 ET
Nephros published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Nephros published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Nephros published news for 2021 q2
SEC form 6
2021-07-12 10:30 ET
Nephros published news for 2021 q2
SEC form 6
2021-07-08 09:22 ET
Nephros published news for 2021 q2
SEC form 6
2021-05-20 17:20 ET
Nephros published news for 2021 q1
SEC form 10
2021-05-06 16:16 ET
Nephros published news for 2021 q1
SEC form 6
2021-05-06 16:15 ET
Nephros published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Nephros published news for 2021 q1
SEC form 6
2021-04-07 16:15 ET
Nephros published news for 2021 q1
SEC form 6
2021-04-05 07:47 ET
Nephros published news for 2021 q1
SEC form 6
2021-03-31 16:15 ET
Nephros published news for 2020 q4
SEC form 6
2021-03-29 17:15 ET
Nephros published news for 2020 q4
SEC form 6
2021-03-01 16:20 ET
Nephros published news for 2020 q4
SEC form 10
2021-03-01 16:16 ET
Nephros published news for 2020 q4
SEC form 6
2021-02-18 16:52 ET
Nephros published news for 2020 q4
SEC form 6
2021-02-03 17:10 ET
Nephros published news for 2020 q4
SEC form 6
2021-01-12 10:51 ET
Nephros published news for 2020 q4
SEC form 6
2020-11-10 18:03 ET
Nephros published news for 2020 q3
SEC form 6
2020-11-05 16:18 ET
Nephros published news for 2020 q3
SEC form 10
2020-11-05 16:06 ET
Nephros published news for 2020 q3
SEC form 6
2020-10-29 16:15 ET
Nephros published news for 2020 q3
SEC form 6
2020-10-20 16:15 ET
Nephros published news for 2020 q3
SEC form 6
2020-10-16 07:45 ET
Nephros published news for 2020 q3
SEC form 6
2020-10-13 16:15 ET
Nephros published news for 2020 q3
SEC form 6
2020-10-06 08:00 ET
Nephros published news for 2020 q3